France’s healthcare and life sciences sector enters 2026 with cautious momentum. With the annual budget finally making its way through the French parliament, stakeholders can look forward to the year ahead in Europe’s second-largest market with increased certainty. And, as this exclusive new report shows, there is plenty to be optimistic about. Healthcare & Life…
Country Reports
Latin America enters 2026 in a state of sharp contradiction. Healthcare and life sciences capabilities are expanding in scale and strategic relevance, even as political volatility and economic uncertainty remain structural features of the region. Recent geopolitical tensions and sanctions rhetoric have once again highlighted how exposed healthcare systems are to currency swings, procurement disruption,…
Switzerland stands as one of the world’s foremost life science hubs, combining scientific depth, industrial strength, and a uniquely collaborative ecosystem. The country hosts a powerful axis of biopharma, diagnostics, and advanced manufacturing stretching from Basel through Zurich, Zug and Rotkreuz, supported by global and regional headquarters, leading R&D centres, and an exceptional talent base.…
Legal & Regulatory
The Pharma Legal Handbook: Asia Growth & Transition Market answers essential questions about the legal and regulatory environment for pharmaceuticals in Estonia, Latvia and Lithuania. It is a must-have for any company operating in Estonia, Latvia and Lithuania or looking to enter these markets. Prepared in association with TEGOS, a leading Baltic law firm, it…
The Pharma Legal Handbook: Market Access & HTA Romania is a comprehensive country-specific market access and health technology assessment (HTA) guide, developed in collaboration with Mușat & Asociații, one of the leading corporate law firms in Romania.
The Pharma Legal Handbook: Slovakia answers essential questions about the legal and regulatory environment for pharmaceuticals in Slovakia. It is a must-have for any company operating in the country or looking to enter the market. Prepared in association with PRK Partners, one of the leading law firms in Slovakia, it should answer any questions linked…
InFocus
Lyon has long played a vital role in global health and today stands as one of Europe’s most investable life sciences hubs. While less well-known than Basel, Barcelona, London, or Paris, Lyon stands out through its tight-knit ecosystem of hospitals, research institutes, pharma and medtech manufacturers, biotechs, and service providers. The density and breadth of…
The global landscape for genomic medicine reached an inflection point in late 2025. First-in-human data confirmed that in vivo CAR-T – once a theoretical ambition – is now a biological reality, capable of extraordinary efficacy in patients with hard-to-treat autoimmune diseases. As this exclusive new Selesta* report shows, China has secured a commanding global lead…
This report is the first in PharmaBoardroom’s InFocus: China Biotech Catalysts series, profiling the companies and leaders shaping the next wave of global biotech innovation. PharmaBoardroom has been at the forefront of China’s biopharma boom for almost 20 years, speaking to founders, pharmas and VCs on the ground and doing more than almost any other…
InFigures
Europe is home to a host of world-leading universal healthcare systems, globally relevant research institutions, and the headquarters of some of the globe’s biggest pharma companies. European science has long had a massive impact, not just for patients on the continent, but globally. However, in recent years Europe has lagged both North America as well…
PharmaBoardroom’s latest report, InFigures: Latin America 2024 features up-to-date datasets from the region’s leading pharma markets and regional production hubs. The combined Latin America and Caribbean market of USD 197 billion looks set to be the fastest growing in the world over the next few years. IQVIA estimates that the Latin American pharma market will…
PharmaBoardroom’s latest report, InFigures: Asia Pacific 2023 features up-to-date datasets from the region’s leading pharma markets and regional innovation hubs. Covering everything from population health to market growth, company rankings, innovation footprints, IPOs, and drug approvals, as well as market-specific executive insight from the PharmaBoardroom archives, this exclusive new report is an excellent jumping-off point…
